RE: Business growth strategy clear and bearing fruit3 Jun 2025 20:54
⤵️See below some cracking posts from earlier today as Laura intimated
This will become very sought after when the wider market catches on to the magnitude of what's about to unfold
RE: ….Today 12:06
Burt....NHS adoption and its minimum £50million alone....and the precision dosing tech can save Billions....
its all there in black and white.....oh and the trial is live and is due to finish end of 2025
KingHomerJ
Posted in: PYC
Posts: 1,779
Price: 0.475
No Opinion
RE: Tyre treadToday 11:32
The Trial is on GCFS…..
The software was initially developed to support clinicians make cancer chemotherapy (docetaxel) dosing decisions, helping to optimise dosing for individual patients to improve patient outcomes. However, as a result of the PARTNER study (completed in January 2023), a second utility was observed, in that the software could be used to support the dosing of an expensive biological drug GCSF. This drug is routinely used in many countries to counteract the toxic effect chemotherapy has on patient's white blood cells - a condition known as neutropenia.
This covers ALL TYPES OF CANCER
GCSF is most expensive treatment on earth
The market is anticipated to reach between $9.17 billion and $12.4 billion by 2032
KingHomerJ
Posted in: PYC
Posts: 1,779
Price: 0.48
No Opinion
RE: Tyre treadToday 11:20
Laura you are forgetting one key thing here..
PYC are currently in a LIVE trial for there precision dosing tool….which is due to finish at the end of the year…..
Any NHS adoption of the device which I’m confident will happen as there has been a significant amount of funding and government policy around this…..this is a company maker on its own and will generate tens of millions annually.
KingHomerJ
Posted in: PYC
Posts: 1,779
Price: 0.48
No Opinion
RE: Without Mathematics, there's no Ai... And PYC uses mathematical models AKA AiToday 11:11
Basil 8p would be very very easy achieved when you look at PYC pipeline and actually revenue Vs other companies that are 15-25 times higher with zero pipeline / products / contracts / revenue/ trials and integrations
KingHomerJ
Posted in: PYC
Posts: 1,779
Price: 0.48
No Opinion
RE: Without Mathematics, there's no Ai... And PYC uses mathematical models AKA AiToday 10:40
The collaboration between Physiomics and DoseMeRx in personalized chemotherapy dosing, particularly for docetaxel, presents significant revenue growth opportunities for both companies.
Physiomics' personalized dosing software, initially available on a research basis, is poised to become a paid feature on the DoseMeRx platform. This shift is expected to establish a recurring revenue stream through licensing or subscription models, Integration with DoseMeRx provides Physiomics access to a broader clinical user base across the US and Europe.
The global oncology market is projected to exceed $500 billion by 2030, with a strong emphasis on p
Sign In
Follow the stocks
